Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial

被引：8

作者：

Smit, E. F. ^{[1
]}

Felip, E. ^{[2
,3
]}

Uprety, D. ^{[4
]}

Nakagawa, K. ^{[5
]}

Paz-Ares, L. ^{[6
]}

Pacheco, J. ^{[7
,8
]}

Li, B. T. ^{[9
]}

Planchard, D. ^{[10
]}

Baik, C. ^{[11
]}

Goto, Y. ^{[12
]}

Murakami, H. ^{[13
]}

Saltos, A. ^{[14
]}

Saxena, K. ^{[15
]}

Shiga, R. ^{[16
]}

Cheng, Y. ^{[17
]}

Yan, Q. ^{[18
]}

Feng, W. ^{[19
]}

Janne, P. A. ^{[20
,21
]}

机构：

[1] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands

[2] Vall Hebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain

[3] Vall Hebron Inst Oncol, Barcelona, Spain

[4] Barbara Ann Karmanos Canc Inst, Med Oncol, Detroit, MI USA

[5] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan

[6] Univ Navarra, Dept Med Oncol, Univ Navarra Clin, Navarra, Spain

[7] Univ Colorado Anschutz, Internal Med, Aurora, CO USA

[8] Univ Colorado Anschutz, Div Med Oncol, Aurora, CO USA

[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[10] Gustave Roussy, Med Oncol, Thorac Team, Villejuif, France

[11] Univ Washington, Thorac Head & Neck Med Oncol, Seattle, WA USA

[12] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan

[13] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[14] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL USA

[15] Daiichi Sankyo Inc, R&D, Basking Ridge, NJ USA

[16] Daiichi Sankyo Inc, Global Oncol R&D, Basking Ridge, NJ USA

[17] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA

[18] Daiichi Sankyo Inc, Biostat, Basking Ridge, NJ USA

[19] Daiichi Sankyo Inc, Global Compan Diagnost, Basking Ridge, NJ USA

[20] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA

[21] Belfer Ctr Appl Canc Sci, Boston, MA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1103

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

975P

引用

页码：S994 / S995

页数：2

共 50 条

[31] Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Takayuki Yoshino
Maria Di Bartolomeo
Kanwal Raghav
Toshiki Masuishi
Fotios Loupakis
Hisato Kawakami
Kensei Yamaguchi
Tomohiro Nishina
Zev Wainberg
Elena Elez
Javier Rodriguez
Marwan Fakih
Fortunato Ciardiello
Kapil Saxena
Kojiro Kobayashi
Emarjola Bako
Yasuyuki Okuda
Gerold Meinhardt
Axel Grothey
Salvatore Siena
[J]. Nature Communications, 14
[32] CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer
Lazaratos, Anna-Maria
Petrecca, Kevin
Guiot, Marie-Christine
Dankner, Matthew
Jerzak, Katarzyna J.
[J]. LANCET ONCOLOGY, 2024, 25 (07): : e282 - e282
[33] Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer
Yardley, Denise A.
Burris, Howard A., III
Hanson, Sarah
Greco, F. Anthony
Spigel, David R.
Barton, John
Hainsworth, John D.
[J]. CLINICAL BREAST CANCER, 2009, 9 (03) : 178 - 183
[34] Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer
Zucchini, G.
Bernardi, A.
Martoni, A.
Zamagni, C.
[J]. ANNALS OF ONCOLOGY, 2013, 24 (01) : 264 - 265
[35] Brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (PTS)
Gori, S.
Rimondini, S.
De Angelis, V.
Sidoni, A.
Mosconi, A. M.
Aristei, C.
Perrucci, E.
Basurto, C.
Franceschi, E.
Scopece, L.
Degli Esposti, R.
Colozza, M.
Crino, L.
[J]. ANNALS OF ONCOLOGY, 2005, 16 : 10 - 11
[36] Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03
Planchard, David
Brahmer, Julie R.
Yang, James C.
Chen, Yuh-Min
Lee, Kang-Yun
Suksombooncharoen, Thatthan
Viglianti, Natasha
Gustavson, Mark
Ragone, Alejandra
Hernandez, Amaya Gasco
[J]. CANCER RESEARCH, 2022, 82 (12)
[37] Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer
Modi, Shanu
Saura, Cristina
Yamashita, Toshinari
Park, Yeon Hee
Kim, Sung-Bae
Tamura, Kenji
Andre, Fabrice
Iwata, Hiroji
Ito, Yoshinori
Tsurutani, Junji
Sohn, Joohyuk
Denduluri, Neelima
Perrin, Christophe
Aogi, Kenjiro
Tokunaga, Eriko
Im, Seock-Ah
Lee, Keun Seok
Hurvitz, Sara A.
Cortes, Javier
Lee, Caleb
Liu, Yali
Zhang, Lin
Shahidi, Javad
Yver, Antoine
Baselga, Jose
Krop, Ian E.
[J]. CANCER RESEARCH, 2021, 81 (04)
[38] Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).
Raghav, Kanwal Pratap Singh
Yoshino, Takayuki
Guimbaud, Rosine
Chau, Ian
Van Den Eynde, Marc
Maurel, Joan
Tie, Jeanne
Kim, Tae Won
Yeh, Kun-Huei
Barrios, Daniel
Kobayashi, Kojiro
Bako, Emarjola
Aregay, Mehreteab
Meinhardt, Gerold
Siena, Salvatore
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02)
Raghav, Kanwal Pratap Singh
Yoshino, Takayuki
Guimbaud, Rosine
Chau, Ian
Van Den Eynde, Marc
Maurel, Joan
Tie, Jeanne
Kim, Tae Won
Yeh, Kun-Huei
Barrios, Daniel
Kobayashi, Kojiro
Bako, Emarjola
Aregay, Mehreteab
Meinhardt, Gerold
Siena, Salvatore
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[40] The role of HER2/neu expression and trastuzumab in non-small cell lung cancer
Hirsch, FR
Langer, CJ
[J]. SEMINARS IN ONCOLOGY, 2004, 31 (01) : 75 - 82

← 1 2 3 4 5 →